Catalyst Capital Advisors LLC Incyte Corp Transaction History

Catalyst Capital Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 10, 2022	SELL	$66.02 - $79.71 $8,054 - $9,724	-122 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$63.34 - $74.11 $696 - $815	-11 Reduced 8.27%	122 $9,000
Q3 2021 Nov 09, 2021	SELL	$68.67 - $84.02 $137 - $168	-2 Reduced 1.48%	133 $9,000
Q2 2021 Aug 06, 2021	BUY	$79.87 - $87.53 $399 - $437	5 Added 3.85%	135 $11,000
Q1 2021 May 10, 2021	SELL	$76.02 - $100.5 $1,824 - $2,412	-24 Reduced 15.58%	130 $11,000
Q4 2020 Feb 05, 2021	BUY	$80.74 - $97.7 $12,433 - $15,045	154 New	154 $13,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.6B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Catalyst Capital Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Catalyst Capital Advisors LLC with notifications on news.